LENZ Therapeutics (NASDAQ:LENZ) Stock Price Target Lowered at Citigroup

Posted by Brenda Bartman on Nov 5th, 2026

LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) had its target price decreased by research analysts at Citigroup from $10.00 to $9.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup‘s price target indicates a potential upside of 199.00% from the stock’s previous close.

Several other equities analysts have also recently commented on LENZ. Weiss Ratings cut shares of LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 9th. Zacks Research raised LENZ Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. HC Wainwright lowered their price objective on LENZ Therapeutics to $16.00 and set a “buy” rating for the company in a report on Friday, October 30th. Finally, Piper Sandler cut their price objective on LENZ Therapeutics from $7.00 to $5.00 and set a “neutral” rating on the stock in a research note on Monday, October 19th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, LENZ Therapeutics currently has a consensus rating of “Hold” and an average target price of $14.75.

View Our Latest Stock Report on LENZ

LENZ Therapeutics Price Performance

LENZ traded down $0.45 during trading on Thursday, hitting $3.01. The company had a trading volume of 734,993 shares, compared to its average volume of 933,041. LENZ Therapeutics has a 1-year low of $2.80 and a 1-year high of $32.13. The company has a market cap of $94.57 million, a PE ratio of -0.67 and a beta of 0.78. The business has a 50-day moving average of $3.99 and a 200-day moving average of $7.89.

LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.10). The company had revenue of $3.38 million for the quarter, compared to analyst estimates of $4.20 million. LENZ Therapeutics had a negative return on equity of 56.10% and a negative net margin of 1,134.97%. Research analysts forecast that LENZ Therapeutics will post -4.08 earnings per share for the current year.

Insiders Place Their Bets

In other LENZ Therapeutics news, major shareholder Ra Capital Management, L.P. sold 2,718,684 shares of the firm’s stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $3.36, for a total value of $9,134,778.24. Following the transaction, the insider owned 57,559 shares of the company’s stock, valued at $193,398.24. This trade represents a 97.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 8.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On LENZ Therapeutics

Institutional investors have recently made changes to their positions in the stock. Inscription Capital LLC acquired a new stake in shares of LENZ Therapeutics during the 3rd quarter worth approximately $44,000. Pinnacle Wealth Planning Services Inc. boosted its position in LENZ Therapeutics by 92.5% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 10,104 shares of the company’s stock valued at $39,000 after purchasing an additional 4,854 shares during the period. Squarepoint Ops LLC increased its position in LENZ Therapeutics by 16.0% in the second quarter. Squarepoint Ops LLC now owns 1,747,096 shares of the company’s stock worth $9,924,000 after buying an additional 240,597 shares during the period. Corient Private Wealth LP increased its position in LENZ Therapeutics by 101.1% in the second quarter. Corient Private Wealth LP now owns 74,931 shares of the company’s stock worth $426,000 after buying an additional 37,672 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new stake in LENZ Therapeutics in the second quarter valued at $102,000. 54.32% of the stock is owned by institutional investors.

LENZ Therapeutics Company Profile

(Get Free Report)

LENZ Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for the treatment of presbyopia, the age-related loss of near vision. The company is headquartered in San Diego, California, and its programs are designed to provide an alternative to reading glasses and other corrective lenses.

LENZ’s primary product candidate is aceclidine ophthalmic solution, developed under the names LNZ100 and VIZZ. The pupil-selective miotic is intended to improve near vision while preserving distance vision, without relying on the lens-shaping mechanism targeted by some other presbyopia treatments.